Nothing Special   »   [go: up one dir, main page]

JPWO2023120405A1 - - Google Patents

Info

Publication number
JPWO2023120405A1
JPWO2023120405A1 JP2023569389A JP2023569389A JPWO2023120405A1 JP WO2023120405 A1 JPWO2023120405 A1 JP WO2023120405A1 JP 2023569389 A JP2023569389 A JP 2023569389A JP 2023569389 A JP2023569389 A JP 2023569389A JP WO2023120405 A1 JPWO2023120405 A1 JP WO2023120405A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569389A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023120405A1 publication Critical patent/JPWO2023120405A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2023569389A 2021-12-23 2022-12-16 Pending JPWO2023120405A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021209565 2021-12-23
PCT/JP2022/046359 WO2023120405A1 (en) 2021-12-23 2022-12-16 COMPOSITION FOR MINIMIZING PRODUCTION AND/OR ACCUMULATION OF AMYLOID β

Publications (1)

Publication Number Publication Date
JPWO2023120405A1 true JPWO2023120405A1 (en) 2023-06-29

Family

ID=86902612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569389A Pending JPWO2023120405A1 (en) 2021-12-23 2022-12-16

Country Status (3)

Country Link
JP (1) JPWO2023120405A1 (en)
TW (1) TW202342088A (en)
WO (1) WO2023120405A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024095906A1 (en) * 2022-11-01 2024-05-10 サントリーホールディングス株式会社 Composition for preventing or inhibiting inflammation of neural cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011055247A1 (en) * 2009-11-09 2011-05-12 Jawaharlal Nehru Centre For Advanced Scientific Research A synthetic cyclic dipeptide and a process thereof
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
JP6669750B2 (en) * 2015-07-16 2020-03-18 サントリーホールディングス株式会社 Composition for inhibiting serum carnosine degrading enzyme containing cyclic dipeptide
JP6687619B2 (en) * 2015-07-17 2020-04-22 サントリーホールディングス株式会社 Composition for antagonisting melanin-concentrating hormone receptor
WO2017119481A1 (en) * 2016-01-08 2017-07-13 サントリーホールディングス株式会社 Cyclic dipeptide-containing composition for preventing neurological diseases
JP6598412B1 (en) * 2019-06-04 2019-10-30 ゼライス株式会社 Food for improving cognitive function

Also Published As

Publication number Publication date
WO2023120405A1 (en) 2023-06-29
TW202342088A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112023005462A2 (en)
BR112023012656A2 (en)
BR112021014123A2 (en)
BR112022009896A2 (en)
BR112022024743A2 (en)
BR112023009656A2 (en)
JPWO2023120405A1 (en)
JPWO2023120407A1 (en)
BR112023004146A2 (en)
BR112022026905A2 (en)
BR112023006729A2 (en)
BR102021018859A2 (en)
BR102021015500A2 (en)
BR112021017747A2 (en)
BR102021007058A2 (en)
BR112023008622A2 (en)
BR112023011738A2 (en)
BR112023016292A2 (en)
BR112023011539A2 (en)
BR112023011610A2 (en)
BR112023008976A2 (en)
BR102021020147A2 (en)
BR102021018926A2 (en)
BR102021018167A2 (en)
BR102021017576A2 (en)